128 related articles for article (PubMed ID: 38016019)
1. Base editing of the mutated TERT promoter inhibits liver tumor growth.
Zhao G; Ma Q; Yang H; Jiang H; Xu Q; Luo S; Meng Z; Liu J; Zhu L; Lin Q; Li M; Fang J; Ma L; Qiu W; Mao Z; Lu Z
Hepatology; 2024 Jun; 79(6):1310-1323. PubMed ID: 38016019
[TBL] [Abstract][Full Text] [Related]
2. Programmable base editing of mutated TERT promoter inhibits brain tumour growth.
Li X; Qian X; Wang B; Xia Y; Zheng Y; Du L; Xu D; Xing D; DePinho RA; Lu Z
Nat Cell Biol; 2020 Mar; 22(3):282-288. PubMed ID: 32066906
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
Tang Q; Hu G; Sang Y; Chen Y; Wei G; Zhu M; Chen M; Li S; Liu R; Peng Z
Clin Transl Med; 2024 May; 14(5):e1703. PubMed ID: 38769666
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.
Yuan X; Dai M; Xu D
Cancer Lett; 2020 Nov; 493():1-9. PubMed ID: 32768523
[TBL] [Abstract][Full Text] [Related]
5. Targeting oncogenic TERT promoter variants by allele-specific epigenome editing.
Kouroukli AG; Rajaram N; Bashtrykov P; Kretzmer H; Siebert R; Jeltsch A; Bens S
Clin Epigenetics; 2023 Nov; 15(1):183. PubMed ID: 37993930
[TBL] [Abstract][Full Text] [Related]
6. GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
Yuan X; Mu N; Wang N; Strååt K; Sofiadis A; Guo Y; Stenman A; Li K; Cheng G; Zhang L; Kong F; Ekblad L; Wennerberg J; Nilsson IL; Juhlin CC; Larsson C; Xu D
Oncogene; 2019 Feb; 38(7):965-979. PubMed ID: 30181547
[TBL] [Abstract][Full Text] [Related]
7. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF
Gabler L; Lötsch D; Kirchhofer D; van Schoonhoven S; Schmidt HM; Mayr L; Pirker C; Neumayer K; Dinhof C; Kastler L; Azizi AA; Dorfer C; Czech T; Haberler C; Peyrl A; Kumar R; Slavc I; Spiegl-Kreinecker S; Gojo J; Berger W
Acta Neuropathol Commun; 2019 Aug; 7(1):128. PubMed ID: 31391125
[TBL] [Abstract][Full Text] [Related]
8. Targeted dual base editing with Campylobacter jejuni Cas9 by single AAV-mediated delivery.
Kweon J; Jang AH; Kwon E; Kim U; Shin HR; See J; Jang G; Lee C; Koo T; Kim S; Kim Y
Exp Mol Med; 2023 Feb; 55(2):377-384. PubMed ID: 36720917
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.
Vallarelli AF; Rachakonda PS; André J; Heidenreich B; Riffaud L; Bensussan A; Kumar R; Dumaz N
Oncotarget; 2016 Aug; 7(33):53127-53136. PubMed ID: 27449293
[TBL] [Abstract][Full Text] [Related]
10. Adenine base editing in an adult mouse model of tyrosinaemia.
Song CQ; Jiang T; Richter M; Rhym LH; Koblan LW; Zafra MP; Schatoff EM; Doman JL; Cao Y; Dow LE; Zhu LJ; Anderson DG; Liu DR; Yin H; Xue W
Nat Biomed Eng; 2020 Jan; 4(1):125-130. PubMed ID: 31740768
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma.
Sze KM; Ho DW; Chiu YT; Tsui YM; Chan LK; Lee JM; Chok KS; Chan AC; Tang CN; Tang VW; Lo IL; Yau DT; Cheung TT; Ng IO
Hepatology; 2021 Jan; 73(1):23-40. PubMed ID: 32170761
[TBL] [Abstract][Full Text] [Related]
12. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
[TBL] [Abstract][Full Text] [Related]
13. Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma.
Kim YJ; Yoo JE; Jeon Y; Chong JU; Choi GH; Song DG; Jung SH; Oh BK; Park YN
Int J Cancer; 2018 Dec; 143(12):3155-3168. PubMed ID: 29987895
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
[TBL] [Abstract][Full Text] [Related]
15.
Hafezi F; Jaxel L; Lemaire M; Turner JD; Perez-Bercoff D
Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944589
[No Abstract] [Full Text] [Related]
16. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
Ko E; Seo HW; Jung ES; Kim BH; Jung G
Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
[TBL] [Abstract][Full Text] [Related]
17. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated TERT promoter mutations abrogate telomerase silencing.
Chiba K; Johnson JZ; Vogan JM; Wagner T; Boyle JM; Hockemeyer D
Elife; 2015 Jul; 4():. PubMed ID: 26194807
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter alterations could provide a solution for Peto's paradox in rodents.
Vedelek B; Maddali AK; Davenova N; Vedelek V; Boros IM
Sci Rep; 2020 Nov; 10(1):20815. PubMed ID: 33257697
[TBL] [Abstract][Full Text] [Related]
20. A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression.
Xi L; Schmidt JC; Zaug AJ; Ascarrunz DR; Cech TR
Genome Biol; 2015 Nov; 16():231. PubMed ID: 26553065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
